Lynparza Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

20 May 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck& Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR)...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news